Costs for CAR T-cell therapies will be far higher than many have imagined, reaching $1 million or more per patient, according to leading cancer experts. The next CAR T-cell drug could be approved as soon as November.

The health care growth rate is falling, but employers aren't feeling any relief.

Mark Gaunya and Jennifer Borislow lay out how the government, Big Pharma, hospital systems, and health insurance companies are incentivized to stop price deflation and maintain complexity.

According to a HealthMine survey of consumers with sponsored health insurance, 39 percent of whom say their plans dont offer them a tool to help them predict how much their care will cost them.